People with a diagnosis of bipolar disorder who are depressed will have a light-based imaging of the brain (Near Infrared Spectroscopy) before and after they have treatment for their depression with a standard, approved medication named lurasidone. They will also answer questions about their history, and give blood samples. The goal is to understand the role of mitochondrial activity in bipolar disorder. Healthy volunteers who have never had a psychiatric disorder will have the same procedures, but they will not receive the medication.
Diagnosis of bipolar disorder
Having symptoms of depression
Taking less than three medications for bipolar disorder
Taking any medications that cannot be combined with lurasidone
Any medical problems that are not well treated
Any drug or alcohol use disorders that are moderate or severe
Any severe suicidal ideation, or having had a suicide attempt in the last five years
Single group
Lurasidone (Latuda)
DrugThe medication will be used to understand how the imaging signal changes when symptoms change during treatment.
Bipolar Depression Rating Scale
A measure of depression severity. Higher numbers indicate more symptoms.
Click on the lead sponsor to view all of their trials.
Martin Lan
Lead sponsor
New York State Psychiatric Institute
Sponsor institution
National Institute of Mental Health (NIMH)
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
